{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:03:02Z","timestamp":1792522982713,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/md.0000000000003531","type":"journal-article","created":{"date-parts":[[2016,8,21]],"date-time":"2016-08-21T00:01:53Z","timestamp":1471737713000},"page":"e3531","source":"Crossref","is-referenced-by-count":14,"title":["Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective"],"prefix":"10.1097","volume":"95","author":[{"given":"Zanfina","family":"Ademi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Pasupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210226","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"R2-21-20210226","doi-asserted-by":"crossref","first-page":"J5","DOI":"10.1093\/eurheartj\/sui056","article-title":"Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe","volume":"7","author":"Tendera","year":"2005","journal-title":"Eur Heart J Suppl"},{"key":"R3-21-20210226","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(09)60236-1","article-title":"Heart failure","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"R4-21-20210226","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5694\/mja12.10993","article-title":"Management of heart failure","volume":"199","author":"Krum","year":"2013","journal-title":"Med J Aust"},{"key":"R6-21-20210226","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/heart.86.5.516","article-title":"Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study","volume":"86","author":"Stewart","year":"2001","journal-title":"Heart"},{"key":"R7-21-20210226","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"R8-21-20210226","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-21-20210226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40256-014-0066-3","article-title":"Cost effectiveness of eplerenone in patients with chronic heart failure","volume":"14","author":"Ademi","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"R10-21-20210226","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"R11-21-20210226","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20141","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"key":"R12-21-20210226","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/heartjnl-2011-301323","article-title":"Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction","volume":"98","author":"Schwenkglenks","year":"2012","journal-title":"Heart"},{"key":"R14-21-20210226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5603\/CJ.2013.0093","article-title":"Knowledge about heart failure in primary care: need for strengthening of continuing medical education","volume":"20","author":"Parnicka","year":"2013","journal-title":"Cardiol J"},{"key":"R16-21-20210226","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"R17-21-20210226","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehl382","article-title":"The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator","volume":"28","author":"Yao","year":"2007","journal-title":"Eur Heart J"},{"key":"R25-21-20210226","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"key":"R26-21-20210226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hec.4730030206","article-title":"Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis","volume":"3","author":"Briggs","year":"1994","journal-title":"Health Econ"},{"key":"R27-21-20210226","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00019053-200523060-00001","article-title":"Incorporation of uncertainty in health economic modelling studies","volume":"23","author":"O\u2019Hagan","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"R28-21-20210226","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/bmj.332.7552.1266","article-title":"Review of NICE's recommendations, 1999-2005","volume":"332","author":"Raftery","year":"2006","journal-title":"BMJ"},{"key":"R30-21-20210226","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/ijerph7041835","article-title":"Health economic assessment cost-effectiveness thresholds and other decision criteria","volume":"7","author":"Simoens","year":"2010","journal-title":"Int J Environ Res Public Health"},{"key":"R31-21-20210226","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2014-305673","article-title":"Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms","volume":"100","author":"Lee","year":"2014","journal-title":"Heart"},{"key":"R32-21-20210226","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/11319940-000000000-00000","article-title":"Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS","volume":"10","author":"Zhang","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"R33-21-20210226","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00019053-200523100-00008","article-title":"Eplerenone: a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure","volume":"23","author":"Croom","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"R34-21-20210226","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.acvd.2008.09.001","article-title":"Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study","volume":"101","author":"de Pouvourville","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"key":"R35-21-20210226","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jval.2012.01.004","article-title":"Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure","volume":"15","author":"McKenna","year":"2012","journal-title":"Value Health"},{"key":"R36-21-20210226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10557-006-8282-y","article-title":"Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction\u2014an analysis of the EPHESUS study from a Swiss perspective","volume":"20","author":"Szucs","year":"2006","journal-title":"Cardiovasc Drugs Ther"},{"key":"R37-21-20210226","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"R38-21-20210226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"R39-21-20210226","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000003531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:23:31Z","timestamp":1620959011000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201605030-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003531","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}